Alkermes to acquire Avadel for up to $2.1 billion

Core Viewpoint - Alkermes announced its intention to acquire Avadel Pharmaceuticals for a total consideration of up to $2.1 billion, which will provide access to Avadel's approved drug for excessive daytime sleepiness [1] Company Summary - The acquisition will enhance Alkermes' portfolio by adding a drug that addresses excessive daytime sleepiness, a significant market need [1] - The total acquisition cost is stated to be up to $2.1 billion, indicating a substantial investment by Alkermes in expanding its therapeutic offerings [1]